Celldex Therapeutics, Inc. (NASDAQ:CLDX) Faces Financial Challenges Despite Clinical Progress

Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported an EPS of -$1.22, missing estimates and indicating financial challenges. The company's revenue fell significantly short of expectations, with actual revenue at $121,000 versus an estimated $1.39 million. Despite financial hurdles, Celldex is advancing in clinical trials, with Phase 3 studies for chronic spontaneous urticaria fully enrolled and more studies underway. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a biotechnology company focused on developing tre ...